Bioequivalence study of different brands of vildagliptin in healthy human subjects

Bioequivalence study of different brands of vildagliptin in healthy human subjects

Abstract Background Vildagliptin is a dipeptidyl peptidase-4 inhibitor used to treat diabetes mellitus. No bioequivalence study data have been published for the Indian population comparing bioequivalence of vildagliptin brands Galvus, Zomelis, and Jalra. This study aimed to evaluate the bioequivalen...

Full description

Bibliographic Details
Main Authors: Mahaveer Sharma, S. S. Agrawal
Format: Article
Language:English
Published: SpringerOpen 2021-07-01
Series:Future Journal of Pharmaceutical Sciences
Subjects:
Vildagliptin
Indian population
Schedule Y
Bioequivalence
CDSCO
Online Access:https://doi.org/10.1186/s43094-021-00308-1

Internet

https://doi.org/10.1186/s43094-021-00308-1

Similar Items